# US 2026/0092059 A1 · Broad Spectrum Antiviral Compositions and Methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092059 A1
- Document ID: US20260092059A1
- Status: Published application
- Kind: A1
- Application number: 19/342,999
- Filed: 2025-09-29
- Published: 2026-04-02
- Earliest claimed: 2017-10-18
- Assignees: Evrys Bio, LLC
- Applicants: Evrys Bio, LLC
- Inventors: Stacy Remiszewski; Lillian W. Chiang; Eain Anthony Murphy; Qun Sun; Frank Kayser; Sarah Jocelyn Fink
- Web page: https://patentgrep.com/patent/US20260092059A1

## CPC

- C07D 417/14: containing three or more hetero rings
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/4741: condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5355: Non-condensed oxazines and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/12: Antivirals
- C07D 491/056: with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Novel thiazole- and isoquinoline-containing compounds are presented that are useful for treating and/or preventing broad-spectrum viral infections. Methods of treating and/or preventing broad-specturm viral infections are also presented. These compounds have shown inhibition of HCMV, influenza viruses, Zika virus, BK Virus and RSV replication in cell-based assays.

## Claims

### Claim 1

A method of treating a human cytomegalovirus (HCMV) infection in a subject, the method comprising administering to the subject a therapeutically effective amount of a composition comprising a compound of Formula I:
wherein:
one of X1 and X2 is N and the other is S;
X3 and X4 are independently selected from C and N; and when X3 is C it is optionally substituted with methyl, ethyl, propyl, i-propyl or n-propyl;
one of R1 and R2 is H and the other is a 5- or 6-membered aryl or cycloalkyl with 0 to 3 ring heteroatoms independently selected from N and O and substituted with 0 to 3 groups independently selected from:
═O, C1-6 straight or branched alkyl optionally substituted with —OR12 or NR7R8, C1-6 straight or branched alkoxy optionally substituted with NR7R8 or —OR12, and C3-6 cycloalkyl optionally substituted with —R12, —OR12 or —NR7R8,
or R1 and R2 together form a 5- or 6-membered aryl or cycloalkyl with 0 to 3 ring heteroatoms independently selected from N and O and substituted with 0 to 3 groups independently selected from:
═O, C1-6 straight or branched alkyl optionally substituted with —OR12 or NR7R8, C1-6 straight or branched alkoxy optionally substituted with NR7R8 or —OR12, and C3-6 cycloalkyl optionally substituted with —R12, —OR12 or —NR7R8;
R3 is selected from H, halo, —C≡CH, —C≡N, —OH, —OCF3, —OCHF2, C1-4 straight or branched alkoxy, —SO2(C1-6 alkyl), —N(CH3)2, —C(O)NH2, —NHSO2R7, —C(O)NR7R8, and a ring structure comprising a 5- or 6-membered aryl or a 4-, 5-, or 6-membered cycloalkyl with 0 to 3 ring heteroatoms independently selected from N, O and S and substituted with 0 to 2 groups independently selected from ═O, halo, C1-6 straight or branched alkyl optionally substituted with —OR12 or —NR7R8, C1-6 straight or branched alkoxy optionally substituted with —NR7R8 or —OR12, —C(O)—C1-6 alkyl and —C(O)O—C1-6 alkyl;
R4 is selected from H, halo, —C≡CH, —C≡N, —OH, —OCF3, —OCHF2, C1-4 straight or branched alkoxy, —SO2(C1-6 alkyl), —N(CH3)2, —C(O)NH2, —NHSO2R7, —C(O)NR7R8, a ring structure comprising a 5- or 6-membered aryl or a 4-, 5-, or 6-membered cycloalkyl with 0 to 3 ring heteroatoms independently selected from N, O and S and substituted with 0 to 2 groups independently selected from ═O, halo, C1-6 straight or branched alkyl optionally substituted with —OR12 or —NR7R8, C1-6 straight or branched alkoxy optionally substituted with —NR7R8 or —OR12, —C(O)—C1-6 alkyl and —C(O)O—C1-6 alkyl,
or the R4 group bonds to X4 to form a 5- or 6-membered aryl or cycloalkyl with 0 to 3 ring heteroatoms independently selected from N, O and S and substituted with 0 to 2 groups independently selected from ═O, halo, C1-6 straight or branched alkyl optionally substituted with —OR12 or —NR7R8, C1-6 straight or branched alkoxy optionally substituted with —NR7R8 or —OR12, —C(O)—C1-6 alkyl and —C(O)O—C1-6 alkyl;
provided that:
at least one of R3 and R4 is selected from the group consisting of: H, halo, —C≡CH, —C≡N, —OH, —OCF3, —OCHF2, C1-4 straight or branched alkoxy, —SO2(C1-6 alkyl), —N(CH3)2, —C(O)NH2, —NHSO2R7, and —C(O)NR7R8, and
R3 and R4 are not both H;
R5 is selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, n-butyl, CF3, CH2CF3 and halo;
R6 is selected from the group consisting of H, methyl, ethyl, n-propyl, isopropyl, n-butyl, CF3, CH2CF3, halo, cyclopropylmethyl and C1-4 alkoxy;
R7 and R8 are independently selected, in each instance, from H, C1-6 straight or branched alkyl, C3-6 cycloalkyl, cyclopropylmethyl and cyclobutylmethyl; and
R12 is independently selected, in each instance, from H and C1-4 straight or branched alkyl.
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein:
R3 is selected from the group consisting of:
and —SO2(C1-6 alkyl);
wherein:
R9 is selected from the group consisting of: H, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, C1-6 straight or branched alkyl optionally substituted with —OR12 or —NR7R8, and C1-6 straight or branched alkoxy optionally substituted with —NR7R8; and
R10 and R11 are independently selected from the group consisting of: H, cyclopropyl, cyclopropylmethyl, cyclobutyl, C1-4 straight or branched alkyl optionally substituted with —OR12 or —NR7R8, C1-4 straight or branched alkoxy optionally substituted with —NR7R8.

### Claim 3 (depends on 1)

The method of claim 1, wherein:
R4 is selected from the group consisting of:
and —SO2(C1-6 alkyl);
wherein:
R9 is selected from the group consisting of: H, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, C1-6 straight or branched alkyl optionally substituted with —OR12 or —NR7R8, and C1-6 straight or branched alkoxy optionally substituted with —NR7R8; and
R10 and R11 are independently selected from the group consisting of: H, cyclopropyl, cyclopropylmethyl, cyclobutyl, C1-4 straight or branched alkyl optionally substituted with —OR12 or —NR7R8, C1-4 straight or branched alkoxy optionally substituted with —NR7R8.

### Claim 4 (depends on 1)

The method of claim 1, wherein:
one of R1 and R2 is H and the other is a 5- or 6-membered aryl or cylcloalkyl with 1 to 3 ring heteroatoms independently selected from N and O and substituted with 0 to 2 groups independently selected from:
═O, C1-6 straight or branched alkyl optionally substituted with —OR12 or —NR7R8, C1-6 straight or branched alkoxy optionally substituted with —NR7R8 or —OR12, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, and cyclohexyl,
or R1 and R2 together form a 5- or 6-membered aryl, cylcloalkyl or cycloalkenyl with 1 to 3 ring heteroatoms independently selected from N and O and substituted with 0 to 2 groups independently selected from:
═O, C1-6 straight or branched alkyl optionally substituted with —OR12 or —NR7R8, C1-6 straight or branched alkoxy optionally substituted with —NR7R8 or —OR12, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, and cyclohexyl.

### Claim 5 (depends on 4)

The method of claim 4, wherein:
R3 is selected from the group consisting of:
and —SO2(C1-6 alkyl);
wherein:
R9 is selected from the group consisting of: H, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, C1-6 straight or branched alkyl optionally substituted with —OR12 or —NR7R8, and C1-6 straight or branched alkoxy optionally substituted with —NR7R8; and
R10 and R11 are independently selected from the group consisting of: H, cyclopropyl, cyclopropylmethyl, cyclobutyl, C1-4 straight or branched alkyl optionally substituted with —OR12 or —NR7R8, C1-4 straight or branched alkoxy optionally substituted with —NR7R8.

### Claim 6 (depends on 4)

The method of claim 4, wherein:
R4 is selected from the group consisting of:
and —SO2(C1-6 alkyl);
wherein:
R9 is selected from the group consisting of: H, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, C1-6 straight or branched alkyl optionally substituted with —OR12 or —NR7R8, and C1-6 straight or branched alkoxy optionally substituted with —NR7R8; and
R10 and R11 are independently selected from the group consisting of: H, cyclopropyl, cyclopropylmethyl, cyclobutyl, C1-4 straight or branched alkyl optionally substituted with —OR12 or —NR7R8, C1-4 straight or branched alkoxy optionally substituted with —NR7R8.

### Claim 7 (depends on 4)

The method of claim 4, wherein:
one of R1 and R2 is H and the other is a 5- or 6-membered aryl or cylcloalkyl with at least one N ring heteroatom and 0 to 2 additional ring heteroatoms independently selected from N and O and substituted with 0 to 2 groups independently selected from:
═O, C1-6 straight or branched alkyl optionally substituted with —OR12 or NR7R8, C1-6 straight or branched alkoxy optionally substituted with —NR7R8 or —OR12, and C3-6 cycloalkyl optionally substituted with —R12, —OR12 or —NR7R8.

### Claim 8 (depends on 7)

The method of claim 7, wherein the compound of Formula I is:

### Claim 9 (depends on 7)

The method of claim 7, wherein:
R3 is selected from the group consisting of:
and —SO2(C1-6 alkyl);
wherein:
R9 is selected from the group consisting of: H, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, C1-6 straight or branched alkyl optionally substituted with —OR12 or —NR7R8, and C1-6 straight or branched alkoxy optionally substituted with —NR7R8; and
R10 and R11 are independently selected from the group consisting of: H, cyclopropyl, cyclopropylmethyl, cyclobutyl, C1-4 straight or branched alkyl optionally substituted with —OR12 or —NR7R8, C1-4 straight or branched alkoxy optionally substituted with —NR7R8.

### Claim 10 (depends on 9)

The method of claim 9, wherein the compound of Formula I is selected from the group consisting of:

### Claim 11 (depends on 7)

The method of claim 7, wherein:
R4 is selected from the group consisting of:
and —SO2(C1-6 alkyl);
wherein:
R9 is selected from the group consisting of: H, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, C1-6 straight or branched alkyl optionally substituted with —OR12 or —NR7R8, and C1-6 straight or branched alkoxy optionally substituted with —NR7R8; and
R10 and R11 are independently selected from the group consisting of: H, cyclopropyl, cyclopropylmethyl, cyclobutyl, C1-4 straight or branched alkyl optionally substituted with —OR12 or —NR7R8, C1-4 straight or branched alkoxy optionally substituted with —NR7R8.

### Claim 12 (depends on 7)

The method of claim 7, wherein:
one of R1 and R2 is H and the other is selected from the group consisting of:
wherein:
R9 is selected from the group consisting of: H, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, C1-6 straight or branched alkyl optionally substituted with —OR12 or —NR7R8, and C1-6 straight or branched alkoxy optionally substituted with —NR7R8;
R10 and R11 are independently selected from the group consisting of: H, cyclopropyl, cyclopropylmethyl, cyclobutyl, C1-4 straight or branched alkyl optionally substituted with —OR12 or —NR7R8, C1-4 straight or branched alkoxy optionally substituted with —NR7R8.

### Claim 13 (depends on 12)

The method of claim 12, wherein the compound of Formula I is:

### Claim 14 (depends on 12)

The method of claim 12, wherein:
R3 is selected from the group consisting of:
and —SO2(C1-6 alkyl);
wherein:
R9 is selected from the group consisting of: H, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, C1-6 straight or branched alkyl optionally substituted with —OR12 or —NR7R8, and C1-6 straight or branched alkoxy optionally substituted with —NR7R8; and
R10 and R11 are independently selected from the group consisting of: H, cyclopropyl, cyclopropylmethyl, cyclobutyl, C1-4 straight or branched alkyl optionally substituted with —OR12 or —NR7R8, C1-4 straight or branched alkoxy optionally substituted with —NR7R8.

### Claim 15 (depends on 14)

The method of claim 14, wherein the compound of Formula I is selected from the group consisting of:

### Claim 16 (depends on 12)

The method of claim 12, wherein:
R4 is selected from the group consisting of:
and —SO2(C1-6 alkyl);
wherein:
R9 is selected from the group consisting of: H, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclohexyl, C1-6 straight or branched alkyl optionally substituted with —OR12 or —NR7R8, and C1-6 straight or branched alkoxy optionally substituted with —NR7R8; and
R10 and R11 are independently selected from the group consisting of: H, cyclopropyl, cyclopropylmethyl, cyclobutyl, C1-4 straight or branched alkyl optionally substituted with —OR12 or —NR7R8, C1-4 straight or branched alkoxy optionally substituted with —NR7R8.

### Claim 17 (depends on 16)

The method of claim 16, wherein the compound of Formula I is:

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23

The method of claim, wherein the method further comprises administering a therapeutically effective amount of an antiviral agent.

### Claim 24 (depends on 23)

The method of claim 23, wherein the antiviral agent is selected from the group consisting of: acyclovir, docosanol, ribarivin, interferons, and the like; cellulose acetate, carbopol and carrageenan, pleconaril, amantidine, rimantidine, fomivirsen, zidovudine, lamivudine, zanamivir, oseltamivir, brivudine, abacavir, adefovir, amprenavir, arbidol, atazanavir, atripla, cidofovir, combivir, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, famciclovir, fosamprenavir, foscarnet, fosfonet, ganciclovir, gardasil, ibacitabine, imunovir, idoxuridine, imiquimod, indinavir, inosine, integrase inhibitor, lamivudine, lopinavir, loviride, mk-0518, maraviroc, moroxydine, nelfinavir, nevirapine, nexavir, nucleotide and/or nucleoside analogues, oseltamivir, penciclovir, peramivir, podophyllotoxin, rimantadine, ritonavir, saquinavir, stavudine, tenofovir, tenofovir disoproxil, tipranavir, trifluridine, trizivir, tromantadine, truvada, valaciclovir, valganciclovir, vicriviroc, vidarabine, viramidine, zalcitabine, morpholino oligonucleotides, ribozyme, protease inhibitors, an assembly inhibitor, zidovudine, brincidofovir, favipiravir, nitoxanide, letermovir, maribavir, CMX157 or a combination thereof.
